COPENHAGEN, Jan 5 (Reuters) – Denmark’s Novo Nordisk said on Monday it would make 1.5 mg and 4 mg of its Wegovy weight loss drug available to self-pay patients in the United States starting Jan. 5 at a monthly price of $149.
The company said on its website that it will offer the highest-dose pills, 9 mg and 25 mg, starting on the same date, for $299 per month.
It is said that starting April 15, the price of a 4 mg dose will increase to $199 per month.
advertise
advertise
The U.S. Food and Drug Administration approved the drug on Dec. 22, helping Novo Nordisk as it regains lost ground from rival Eli Lilly and Company.
Semaglutide pills contain the same active ingredient as injectable Wegovy and Ozempic and will be sold under the Wegovy brand name. Novo Nordisk already markets oral semaglutide Rybelsus for the treatment of type 2 diabetes.
(Reporting by Jacob Gronholt-Pedersen; writing by Anna Ringstrom; editing by Terje Solsvik)